{"id":11056,"date":"2022-11-27T07:43:44","date_gmt":"2022-11-27T07:43:44","guid":{"rendered":"https:\/\/marylanddailygazette.com\/centessa-pharmaceuticals-48-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick-foti-llc-remind-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit\/"},"modified":"2022-11-27T07:43:44","modified_gmt":"2022-11-27T07:43:44","slug":"centessa-pharmaceuticals-48-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick-foti-llc-remind-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/centessa-pharmaceuticals-48-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick-foti-llc-remind-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit\/","title":{"rendered":"CENTESSA PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc \u2013 CNTA"},"content":{"rendered":"

CENTESSA PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc \u2013 CNTA<\/a><\/p>\n

NEW ORLEANS, LA \/ ACCESSWIRE \/ November 26, 2022 \/ <\/strong>Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022<\/u><\/strong> to file lead plaintiff applications in a securities class action lawsuit against Centessa Pharmaceuticals plc (NasdaqGS:CNTA), if they purchased or otherwise acquired the Company\u2019s securities between May 28, 2021 and June 1, 2022, inclusive (the \u201cClass Period\u201d) and\/or purchased or otherwise acquired the Company\u2019s American Depositary Shares (\u201cADSs\u201d) pursuant to the Company\u2019s May 2021 initial public offering (the \u201cIPO\u201d). This action is pending in the United States District Court for the Southern District of New York.<\/p>\n

What You May Do<\/strong><\/p>\n

If you purchased securities or ADSs of Centessa as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]<\/span><\/a>), or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-cnta\/<\/a> to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by November 28, 2022<\/u><\/strong>.<\/p>\n

About the Lawsuit<\/strong><\/p>\n

Centessa and certain of its executives are charged with failing to disclose material information during the Class Period and\/or in the Registration Statement and Prospectus issued in conjunction with the initial public offering, violating federal securities laws.<\/p>\n

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) lixivaptan, the Company\u2019s drug product, was less safe than the Company had represented; (ii) the Company overstated lixivaptan\u2019s clinical effectiveness and commercial viability; (iii) ZF874, another of the Company\u2019s drug products, was less safe than the Company had represented; (iv) the Company overstated ZF874\u2019s clinical effectiveness and commercial viability while downplaying the drug\u2019s safety issues; and (v) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., <\/i>No. 22-cv-8805.<\/p>\n

About Kahn Swick & Foti, LLC<\/strong><\/p>\n

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation\u2019s premier boutique securities litigation law firms. KSF serves a variety of clients \u2013 including public institutional investors, hedge funds, money managers and retail investors \u2013 in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.<\/p>\n

To learn more about KSF, you may visit www.ksfcounsel.com<\/a>.<\/p>\n

\"Kahn<\/figure>\n

CONTACT:<\/strong>
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]<\/span><\/u><\/a>
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163<\/p>\n

SOURCE:<\/strong> Kahn Swick & Foti, LLC<\/p>\n

View source version on accesswire.com:
https:\/\/www.accesswire.com\/728695\/CENTESSA-PHARMACEUTICALS-48-HOUR-DEADLINE-ALERT-FORMER-LOUISIANA-ATTORNEY-GENERAL-AND-KAHN-SWICK-FOTI-LLC-REMIND-INVESTORS-WITH-LOSSES-IN-EXCESS-OF-100000-of-Deadline-in-Class-Action-Lawsuit-Against-Centessa-Pharmaceuticals-plc\u2013CNTA<\/a><\/p>\n

Published Sat, 26 Nov 2022 20:05:53 -0600<\/p>\n","protected":false},"excerpt":{"rendered":"

CENTESSA PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc \u2013 CNTA NEW ORLEANS, LA \/ ACCESSWIRE \/ November 26, 2022 \/ Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, […]<\/p>\n","protected":false},"author":3,"featured_media":11055,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/11056"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=11056"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/11056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/11055"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=11056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=11056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=11056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}